Premium
DOSE DENSE ABVD (DD‐ABVD) AS FIRST LINE THERAPY IN EARLY‐STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI
Author(s) -
Mazza R.,
Spina M.,
Califano C.,
Gaudio F.,
Carella M.,
Consoli U.,
Palombi F.,
Musso M.,
Pulsoni A.,
Kovalchuk S.,
Bonfichi M.,
Ricci F.,
Fabbri A.,
Liberati A.,
Rodari M.,
Giordano L.,
Balzarotti M.,
Gallamini A.,
Ricardi U.,
Chauvie S.,
Merli F.,
CarloStella C.,
Santoro A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.100_2630
Subject(s) - abvd , medicine , dacarbazine , clinical endpoint , vinblastine , stage (stratigraphy) , surgery , radiation therapy , nuclear medicine , clinical trial , chemotherapy , vincristine , cyclophosphamide , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom